Neil Parrott

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10509593/publications.pdf

Version: 2024-02-01

35 papers	2,308 citations	257450 24 h-index	361022 35 g-index
38 all docs	38 docs citations	38 times ranked	1919 citing authors

#	Article	IF	Citations
1	A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics. Clinical Pharmacokinetics, 2006, 45, 511-542.	3.5	301
2	The mechanisms of pharmacokinetic food-drug interactions â€“ A perspective from the UNGAP group. European Journal of Pharmaceutical Sciences, 2019, 134, 31-59.	4.0	224
3	Prediction of intestinal absorption: comparative assessment of gastroplusâ„¢ and ideaâ„¢. European Journal of Pharmaceutical Sciences, 2002, 17, 51-61.	4.0	159
4	Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: An UNGAP review. European Journal of Pharmaceutical Sciences, 2019, 134, 153-175.	4.0	146
5	Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling. Clinical Pharmacokinetics, 2006, 45, 1213-1226.	3.5	131
6	Applications of Physiologically Based Absorption Models in Drug Discovery and Development. Molecular Pharmaceutics, 2008, 5, 760-775.	4.6	107
7	A strategy for preclinical formulation development using GastroPlusâ„¢ as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. European Journal of Pharmaceutical Sciences, 2006, 27, 91-99.	4.0	105
8	An Evaluation of the Utility of Physiologically Based Models of Pharmacokinetics in Early Drug Discovery. Journal of Pharmaceutical Sciences, 2005, 94, 2327-2343.	3.3	100
9	Development of a Physiologically Based Model for Oseltamivir and Simulation of Pharmacokinetics in Neonates and Infants. Clinical Pharmacokinetics, 2011, 50, 613-623.	3.5	100
10	Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies. Clinical Pharmacokinetics, 2019, 58, 727-746.	3.5	93
11	Application of Full Physiological Models for Pharmaceutical Drug Candidate Selection and Extrapolation of Pharmacokinetics to Man. Basic and Clinical Pharmacology and Toxicology, 2005, 96, 193-199.	2.5	91
12	Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Advanced Drug Delivery Reviews, 2021, 171, 289-331.	13.7	84
13	A Physiologically Based Pharmacokinetic Model of the Minipig: Data Compilation and Model Implementation. Pharmaceutical Research, 2013, 30, 1-15.	3.5	75
14	Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration. European Journal of Pharmaceutical Sciences, 2014, 56, 1-15.	4.0	65
15	Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates â€“ An evaluation and case study using GastroPlusâ„¢. European Journal of Pharmaceutical Sciences, 2012, 47, 375-386.	4.0	63
16	Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS Journal, 2020, 22, 123.	4.4	53
17	Quantitative ADME Proteomics â€“ CYP and UGT Enzymes in the Beagle Dog Liver and Intestine. Pharmaceutical Research, 2015, 32, 74-90.	3.5	47
18	Applications of a 7-day Caco-2 cell model in drug discovery and development. European Journal of Pharmaceutical Sciences, 2014, 56, 120-130.	4.0	38

#	Article	IF	Citations
19	Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib. AAPS Journal, 2020, 22, 78.	4.4	35
20	Mass Spectrometry-Based Quantification of CYP Enzymes to Establish In Vitro/In Vivo Scaling Factors for Intestinal and Hepatic Metabolism in Beagle Dog. Pharmaceutical Research, 2012, 29, 1832-1842.	3.5	29
21	Physiologically Based Absorption Modelling to Predict the Impact of Drug Properties on Pharmacokinetics of Bitopertin. AAPS Journal, 2014, 16, 1077-1084.	4.4	29
22	Pharmacokinetics of Paracetamol in GÃ¶ttingen Minipigs: In Vivo Studies and Modeling to Elucidate Physiological Determinants of Absorption. Pharmaceutical Research, 2014, 31, 2696-2707.	3.5	28
23	The great barrier belief: The bloodâ€“brain barrier and considerations for juvenile toxicity studies. Reproductive Toxicology, 2017, 72, 129-135.	2.9	28
24	The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development. Proteomics - Clinical Applications, 2015, 9, 732-744.	1.6	27
25	Understanding Mechanisms of Food Effect and Developing Reliable PBPK Models Using a Middle-out Approach. AAPS Journal, 2021, 23, 12.	4.4	23
26	In Vitro to in Vivo Extrapolation and Physiologically Based Modeling of Cytochrome P450 Mediated Metabolism in Beagle Dog Gut Wall and Liver. Molecular Pharmaceutics, 2013, 10, 1388-1399.	4.6	19
27	Investigating Oral Absorption of Carbamazepine in Pediatric Populations. AAPS Journal, 2017, 19, 1864-1877.	4.4	19
28	Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery. Molecular Pharmaceutics, 2022, 19, 2203-2216.	4.6	17
29	Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine. AAPS Journal, 2020, 22, 128.	4.4	16
30	Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin. Clinical Pharmacokinetics, 2013, 52, 673-683.	3.5	14
31	Characterization of Pharmacokinetics in the GÃ¶ttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. Pharmaceutical Research, 2016, 33, 2565-2579.	3.5	14
32	Use of physiologically based pharmacokinetic modeling for assessment of drugâ€“drug interactions. Future Medicinal Chemistry, 2012, 4, 681-693.	2.3	10
33	PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5â€²-Diphospho-glucuronosyltransferase Substrates. Pharmaceutics, 2021, 13, 1325.	4.5	9
34	Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans. Xenobiotica, 2016, 46, 667-676.	1.1	5
35	Interspecies Scaling. , 2004, , 133-175.		3